Capsule Summary Slidesets

Share

Program Content

Activities

  • Bomedemstat Plus Ruxolitinib for MF
    Phase II Study of Bomedemstat Plus Ruxolitinib for Patients With Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • TRANSFORM 1
    TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • RuxoBEAT
    RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • Bomedemstat in ET
    Phase IIb Trial of LSD1 Inhibitor Bomedemstat in Patients With Essential Thrombocythemia Resistant or Intolerant to Standard Therapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2023

  • MANIFEST 2
    MANIFEST-2: Phase III Trial of Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib for JAK Inhibitor–Naive Myelofibrosis
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.